Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab

BACKGROUND: Few studies investigated the immune response to SARS-CoV-2 vaccine in patients with multiple sclerosis (pwMS) treated with natalizumab (NTZ) and found a short-term efficient humoral response; however, there are no studies assessing the levels of SARS-CoV-2 IgG antibodies in pwMS treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Altieri, Manuela, Capuano, Rocco, Conte, Miriana, Donnarumma, Giovanna, Grimaldi, Elena, Coppola, Nicola, Galdiero, Massimiliano, d’Ambrosio, Alessandro, Tedeschi, Gioacchino, Gallo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853307/
https://www.ncbi.nlm.nih.gov/pubmed/35171373
http://dx.doi.org/10.1007/s10072-022-05940-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853307/
https://www.ncbi.nlm.nih.gov/pubmed/35171373
http://dx.doi.org/10.1007/s10072-022-05940-0

Ejemplares similares